Diagnosis and risk stratification in patients with anti-RNP autoimmunity

Lupus

Volumn 24, Issue 10, 2015, Pages 1057-1066

  Carpintero, M F ^a   Martinez, L ^b   Fernandez, I ^a   Garza Romero, A C ^a   Mejia, C ^a   Zang, Y J ^a   Hoffman, R W ^c   Greidinger, E L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

classification criteria; inflammation; mixed connective tissue disease; Systemic lupus erythematosus

Indexed keywords

B CELL MATURATION ANTIGEN; BIOLOGICAL MARKER; INTERFERON; RIBONUCLEOPROTEIN ANTIBODY; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR ALPHA; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; RIBONUCLEOPROTEIN; RNA;

ADULT; ALARCON SEGOVIA CRITERIA; ARTICLE; AUTOIMMUNITY; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; FEMALE; HUMAN; IMMUNOREACTIVITY; KIDNEY DISEASE; LOW RISK PATIENT; LUPUS INTERNATIONAL COLLABORATING CLINIC CRITERIA; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RISK ASSESSMENT; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; PROCEDURES;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE EXPRESSION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; RAYNAUD DISEASE; RIBONUCLEOPROTEINS; RISK ASSESSMENT; RNA;

EID: 84938811915     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315575586     Document Type: Article

References (37)

1. Alarcón-Segovia D, Cardiel MH,. Comparison between 3 diagnostic criteria for mixed connective tissue disease: study of 593 patients. J Rheumatol 1989; 16: 328-334.
2. Burdt MA, Hoffman RW, Deutscher SL,. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42: 899-909.
3. Kirou KA, Lee C, George S,. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-1503.
4. Arbuckle MR, McClain MT, Rubertone MV,. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
5. Petri M, Orbai A-M, Alarcon GS,. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686.
6. Cappelli S, Bellando Randone S, Martinović D,. "To be or not to be", ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012; 4: 589-598.
7. Gunnarsson R, Molberg O, Gilboe IM,. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis 2011; 70: 1047-1051.
8. Petri M, Wallace DJ, Spindler A,. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013; 65 (4): 1011-1021.
9. Manzi S, Sánchez-Guerrero J, Merrill JT,. BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71: 1833-1838.
10. Zimmer R, Scherbarth HR, Rillo OL,. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013; 72: 1830-1835.
11. Bodolay E, Aleksza M, Antal-Szalmás P,. Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease. J Rheumatol 2002; 29: 2136-2142.
12. Jinnin M, Ihn H, Yazawa N,. Elevated circulating soluble CD40 ligand in patients with mixed connective tissue disease. Clin Rheumatol 2003; 22: 37-39.
13. Bakri Hassan A, Rönnelid J, Gunnarsson I,. Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease. J Autoimmun 1998; 11: 503-508.
14. Holyst MM, Hill DL, Hoch SO,. Analysis of human T cell and B cell responses against U small nuclear ribonucleoprotein 70-kd, B, and D polypeptides among patients with systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum 1997; 40: 1493-1503.
15. Alcocer-Varela J, Laffón A, Alarcón-Segovia D,. Differences in the production of and/or the response to interleukin-2 by T lymphocytes from patients with the various connective tissue diseases. Rheumatol Int 1984; 4: 39-44.
16. Greidinger EL, Zang Y, Martinez L,. Differential tissue targeting of autoimmunity manifestations by autoantigen-associated Y RNAs. Arthritis Rheum 2007; 56: 1589-1597.
17. Greidinger EL, Foecking MF, Magee J,. A major B cell epitope present on the apoptotic but not the intact form of the U1-70-kDa ribonucleoprotein autoantigen. J Immunol 2004; 172: 709-716.
18. Maldonado ME, Perez M, Pignac-Kobinger J,. Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population. J Rheumatol 2008; 35: 429-437.
19. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
20. Alarcón-Segovia D, Cardiel MH,. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989; 16: 328-334.
21. Gladman DD, Ibañez D, Urowitz MB,. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
22. Szodoray P, Hajas A, Kardos L,. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus 2012; 21: 1412-1422.
23. Chung L, Liu J, Parsons L,. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-1394.
24. Gunnarsson R, Andreassen AK, Molberg Ø. Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology (Oxford) 2013; 52: 1208-1213.
25. Weinrich MC, Maricq HR, Keil JE,. Prevalence of Raynaud phenomenon in the adult population of South Carolina. J Clin Epidemiol 1990; 43: 1343-1349.
26. Wang B, Higgs BW, Chang L,. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-a receptor therapy. Clin Pharmacol Ther 2013; 93: 483-492.
27. Higgs BW, Liu Z, White B,. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70: 2029-2036.
28. Masi AT,. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
29. van den Hoogen F, Khanna D, Fransen J,. 2013 Classification Criteria for Systemic Sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis 2013; 72: 1747-1755.
30. O'Connor BP, Raman VS, Erickson LD,. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91-98.
31. Cambridge G, Leandro MJ, Teodorescu M,. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54: 3612-3622.
32. Tsuji S1, Cortesão C, Bram RJ,. TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood 2011; 118: 5832-5839.
33. Hajas A, Barath S, Szodoray P,. Derailed B cell homeostasis in patients with mixed connective tissue disease. Hum Immunol 2013; 74: 833-841.
34. Mesa A, Wu W, Martinez L,. Differential immunoglobulin class-mediated responses to the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease. Lupus 2013; 22: 1371-1381.
35. He B, Santamaria R, Xu W,. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nature Immunology 2010; 11: 836-845.
36. Greidinger EL, Zang Y, Jaimes K,. A murine model of mixed connective tissue disease (MCTD) induced with U1-snRNP autoantigen. Arthritis Rheum 2006; 54: 661-669.
37. Greidinger EL, Zang Y, Fernandez I,. Tissue targeting of anti-RNP autoimmunity: Effects of T cells and myeloid dendritic cells in a murine model. Arthritis Rheum 2009; 60: 534-542.